173 completed, 26 terminated, 26 unknown, 7 recruiting. 66 Phase 3, 61 Phase 2, 51 Phase 4, 34 Not applicable, 31 Phase 1.
Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) Lopinavir / ritonavir - Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection | Phase 2 | Recruiting | Daré Bioscience, Inc. | 118 | 2026-07-17 | 2026-11-06 |
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Lopinavir/Ritonavir in PLWH With High-Grade AIN Lopinavir / Ritonavir - High-Grade Anal Intraepithelial Neoplasia | Phase 1 | Recruiting | University of Wisconsin, Madison | 21 | 2023-12-19 | 2026-05-15 |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | DualityBio Inc. | 862 | 2023-08-17 | 2026-10-21 |
| Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA) - HIV, Tuberculosis | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 205 | 2021-09-01 | 2026-08-26 | |
| Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year Lopinavir/Ritonavir, Placebo Administration, Questionnaire Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2021-05-01 | 2021-04-26 | |
| Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 294 | 2020-11-27 | 2024-12-27 |
| Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients Remdesivir, Lopinavir/ Ritonavir and Remdesivir combination - Covid19 | Phase 4 | Unknown | Ahmed Essam | 90 | 2020-11-01 | 2021-03-17 |
| Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. Remdesivir, Hydroxychloroquine, Tocilizumab - Covid19, Pneumonia | Phase 4 | Unknown | October 6 University | 150 | 2020-10-01 | 2021-03-17 |
| FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals Favipiravir, Lopinavir/ Ritonavir, Favipiravir Placebo - COVID-19 | Phase 2 | Completed | University College, London | 240 | 2020-09-24 | 2022-12-15 |
| the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19 | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 100 | 2020-08-20 | 2020-08-20 |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" Hydroxychloroquine Sulfate Tablets, Lopinavir/ Ritonavir Oral Tablet, Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets - COVID-19, Coronavirus Infection | Phase 3 | Unknown | Cardresearch | 1968 | 2020-06-03 | 2021-01-26 |
| Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Lopinavir/Ritonavir 400 mg/100 mg, Placebo - COVID-19 | Phase 2 | Completed | Vanderbilt University Medical Center | 452 | 2020-06-01 | 2024-02-28 |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. Baricitinib - Pharmacological Action | Phase 2 / Phase 3 | Unknown | Hospital of Prato | 200 | 2020-05-16 | 2020-04-22 |
| Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia Xiyanping injection, Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride - 2019 Novel Coronavirus Pneumonia | Unknown | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 426 | 2020-05-15 | 2020-05-20 | |
| OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab - COVID | Phase 3 | Withdrawn | Fondation Hôpital Saint-Joseph | 2020-05-07 | 2021-04-27 | |
| Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions Lopinavir/Ritonavir 200 mg/50 mg Film Tablet, Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet - Bioequivalence | Phase 1 | Completed | World Medicine ILAC SAN. ve TIC. A.S. | 30 | 2020-04-30 | 2020-12-31 |
| Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland Lopinavir/ritonavir - Prevention of COVID-19 | Phase 3 | Completed | Calmy Alexandra | 326 | 2020-04-23 | 2021-04-12 |
| An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 Favipiravir, Standard of Care - COVID-19 | Phase 2 / Phase 3 | Unknown | Chromis LLC | 330 | 2020-04-23 | 2020-06-16 |
Showing 20 of 242. Sign in to see all of them.
HIV Infections (128) · Acquired Immunodeficiency Syndrome (32) · COVID-19 (28) · Coronavirus Infections (9) · Hepatitis C (8) · Tuberculosis (8) · Pneumonia (7) · Infections (6) · Malaria (5) · Breast Feeding (4) · Disease Progression (3) · Lipodystrophy (3) · Coinfection (2) · Community-Acquired Pneumonia (2) · HIV Seropositivity (2)
National Institute of Allergy and Infectious Diseases (NIAID) (34) · Abbott (22) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (7) · University of California, San Francisco (6) · ANRS, Emerging Infectious Diseases (5) · Bristol-Myers Squibb (5) · French National Agency for Research on AIDS and Viral Hepatitis (5) · Kirby Institute (5) · Germans Trias i Pujol Hospital (4) · GlaxoSmithKline (4) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (4) · Shahid Beheshti University of Medical Sciences (4) · The HIV Netherlands Australia Thailand Research Collaboration (4) · ViiV Healthcare (4) · AbbVie (prior sponsor, Abbott) (3)
United States (103) · South Africa (32) · Spain (26) · Puerto Rico (24) · Canada (20) · France (20) · Thailand (19) · Brazil (18) · United Kingdom (18) · Germany (15) · Uganda (14) · Italy (13) · Malawi (13) · Argentina (11) · Australia (11)
Ilad Alavi Darazam, MD (3) · Minoosh Shabani, MD (3) · Mohammadreza Haji Esmaelie, MD (3) · Seyed Sina Naghibi Irvani, MD, MPH, MBA (3) · Shervin Shokouhi, MD (3) · Diane Havlir, MD (2) · Grant Dorsey, MD, PhD (2) · James McIntyre, MBChB, MRCOG (2) · Kiat Ruxrungtham, MD (2) · Kristine B Patterson, MD (2) · Mark Mirochnick, MD (2)
PMID 34473343, PMID 29767684, PMID 33394942, PMID 33570583, PMID 36695483, PMID 37489818, PMID 37988391, PMID 11399973, PMID 11964551, PMID 15090769, PMID 15097312, PMID 15316349, PMID 15668539, PMID 16091248, PMID 16368644, PMID 16470119, PMID 16886163, PMID 16962381, PMID 16988514, PMID 17436219, PMID 17487675, PMID 1750226, PMID 17527093, PMID 1783744, PMID 18090045, PMID 18190257, PMID 18366444, PMID 18480202, PMID 18540803, PMID 18625762, PMID 18636958, PMID 18647794, PMID 18795962, PMID 18989231, PMID 19008157, PMID 19020325, PMID 19209098, PMID 19237646, PMID 19258274, PMID 19275490, PMID 19299471, PMID 19417580, PMID 19424051, PMID 19440326, PMID 19474651, PMID 19479079, PMID 19512937, PMID 19597072, PMID 19648824, PMID 19682100
U01AI068636 (7), U01AI068632 (4), 2005 (2), 2008 (2), U19AI053217 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), 2023 (1), 5UM1AI068634 (1), K23AI077355 (1), P01AI055356 (1), P01HD059454 (1), R01AI051986 (1)